Total Payments
$32,763
2024 Payments
$2,792
Companies
23
Transactions
63
Medicare Patients
1,716
Medicare Billing
$313,746
Payment Breakdown by Category
Other$26,474 (80.8%)
Consulting$4,092 (12.5%)
Food & Beverage$2,017 (6.2%)
Travel$180.11 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $26,474 | 14 | 80.8% |
| Consulting Fee | $4,092 | 2 | 12.5% |
| Food and Beverage | $2,017 | 42 | 6.2% |
| Travel and Lodging | $180.11 | 5 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $31,181 | 25 | $0 (2024) |
| PFIZER INC. | $398.20 | 5 | $0 (2024) |
| Novocure Inc. | $175.00 | 1 | $0 (2017) |
| Janssen Scientific Affairs, LLC | $144.13 | 2 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $139.06 | 4 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $134.61 | 2 | $0 (2017) |
| Genentech USA, Inc. | $97.49 | 1 | $0 (2017) |
| Celgene Corporation | $86.26 | 2 | $0 (2024) |
| Janssen Biotech, Inc. | $49.98 | 3 | $0 (2024) |
| Gilead Sciences, Inc. | $48.25 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,792 | 25 | GENZYME CORPORATION ($2,395) |
| 2023 | $26,896 | 22 | GENZYME CORPORATION ($26,835) |
| 2022 | $2,109 | 3 | GENZYME CORPORATION ($1,952) |
| 2020 | $11.25 | 1 | Lilly USA, LLC ($11.25) |
| 2017 | $955.51 | 12 | PFIZER INC. ($379.20) |
All Payment Transactions
63 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $17.08 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $18.12 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/27/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.90 | General |
| 11/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $25.24 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $32.81 | General |
| Category: Immunology | ||||||
| 10/29/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $20.43 | General |
| Category: Oncology | ||||||
| 10/15/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.86 | General |
| Category: Oncology | ||||||
| 10/08/2024 | Blue Earth Diagnostics Limited | POSLUMA (Drug) | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: Diagnostic Imaging | ||||||
| 10/07/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $16.53 | General |
| Category: Oncology | ||||||
| 10/02/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.27 | General |
| Category: Hematology | ||||||
| 10/01/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: Genetically Defined Disease | ||||||
| 09/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $27.97 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.00 | General |
| 09/10/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: HEMATOLOGY | ||||||
| 08/27/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: Oncology | ||||||
| 08/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.35 | General |
| 08/14/2024 | Blue Earth Diagnostics Limited | POSLUMA (Drug) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: Diagnostic Imaging | ||||||
| 07/01/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 06/20/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $14.26 | General |
| Category: Hematology/Oncology | ||||||
| 05/14/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,140.00 | General |
| 05/14/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $180.73 | General |
| 05/14/2024 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $41.54 | General |
| 05/14/2024 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $32.46 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 460 | 961 | $753,433 | $81,712 |
| 2022 | 7 | 429 | 855 | $702,682 | $75,950 |
| 2021 | 9 | 483 | 835 | $707,007 | $84,284 |
| 2020 | 8 | 344 | 760 | $253,250 | $71,800 |
Total Patients
1,716
Total Services
3,411
Medicare Billing
$313,746
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 178 | 434 | $365,070 | $34,603 | 9.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 106 | 346 | $162,362 | $23,316 | 14.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 63 | 66 | $85,150 | $9,697 | 11.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 56 | 56 | $61,028 | $5,863 | 9.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 39 | 39 | $56,221 | $5,760 | 10.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 18 | 20 | $23,602 | $2,473 | 10.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 155 | 420 | $351,278 | $33,990 | 9.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 85 | 210 | $95,345 | $12,798 | 13.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 56 | 65 | $82,061 | $10,992 | 13.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 64 | 64 | $70,120 | $7,106 | 10.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 33 | 54 | $62,344 | $6,721 | 10.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $25,802 | $2,221 | 8.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 24 | $15,732 | $2,122 | 13.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 137 | 296 | $217,856 | $24,717 | 11.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 96 | 234 | $160,992 | $21,004 | 13.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 63 | 70 | $93,520 | $11,977 | 12.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 57 | 93 | $91,605 | $11,338 | 12.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 53 | 53 | $58,565 | $6,072 | 10.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 30 | 30 | $41,790 | $4,745 | 11.4% |
| 99356 | Prolonged inpatient or observation hospital service, first hour | Facility | 2021 | 20 | 28 | $17,164 | $2,234 | 13.0% |
| 99357 | Prolonged inpatient or observation hospital service each 30 minutes beyond first hour | Facility | 2021 | 14 | 18 | $11,124 | $1,442 | 13.0% |
| 38221 | Biopsy of bone marrow | Facility | 2021 | 13 | 13 | $14,391 | $754.37 | 5.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 100 | 393 | $111,219 | $35,834 | 32.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 83 | 174 | $52,896 | $11,988 | 22.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 41 | 51 | $28,152 | $9,050 | 32.1% |
About Dr. Manish Dave, M.D
Dr. Manish Dave, M.D is a Internal Medicine healthcare provider based in Edison, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/24/2011. The National Provider Identifier (NPI) number assigned to this provider is 1194011478.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Manish Dave, M.D has received a total of $32,763 in payments from pharmaceutical and medical device companies, with $2,792 received in 2024. These payments were reported across 63 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($26,474).
As a Medicare-enrolled provider, Dave has provided services to 1,716 Medicare beneficiaries, totaling 3,411 services with total Medicare billing of $313,746. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology, Hematology & Oncology
- Location Edison, NJ
- Active Since 06/24/2011
- Last Updated 04/11/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1194011478
Products in Payments
- ENJAYMO (Biological) $28,787
- Optune (Device) $175.00
- DARZALEX (Biological) $161.34
- NINLARO (Drug) $159.85
- IBRANCE (Drug) $125.00
- XALKORI (Drug) $125.00
- SUTENT (Drug) $115.32
- OPDIVO (Biological) $105.45
- ONUREG (Drug) $68.99
- KRAZATI (Drug) $33.61
- Fabhalta (Drug) $32.81
- POSLUMA (Drug) $32.74
- Nubeqa (Drug) $27.97
- PRECISETUMOR (Device) $22.29
- PYRUKYND (Drug) $21.81
- RYBREVANT (Drug) $20.43
- MONOFERRIC (Drug) $19.43
- BOSULIF (Drug) $19.00
- CABOMETYX (Drug) $18.12
- REBLOZYL (Biological) $17.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Edison
Mrs. Debra Goldstein, Md, MD
Internal Medicine — Payments: $87,115
Internal Medicine $87,115
Dr. Sagar Desai, M.d, M.D
Internal Medicine — Payments: $11,106
Internal Medicine $11,106
Lisa Casale, M.d, M.D
Internal Medicine — Payments: $10,137
Internal Medicine $10,137
Dr. Ram Bangalore, M.d, M.D
Internal Medicine — Payments: $9,963
Internal Medicine $9,963
Chintan Modi, M.d, M.D
Internal Medicine — Payments: $9,780
Internal Medicine $9,780
Dr. Girija Bhakey, Md, MD
Internal Medicine — Payments: $8,623
Internal Medicine $8,623